Literature DB >> 9535664

Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.

M R Malinow1, P B Duell, D L Hess, P H Anderson, W D Kruger, B E Phillipson, R A Gluckman, P C Block, B M Upson.   

Abstract

BACKGROUND: The Food and Drug Administration (FDA) has recommended that cereal-grain products be fortified with folic acid to prevent congenital neural-tube defects. Since folic acid supplementation reduces levels of plasma homocyst(e)ine, or plasma total homocysteine, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid fortification might reduce plasma homocyst(e)ine levels.
METHODS: To test this hypothesis, we assessed the effects of breakfast cereals fortified with three levels of folic acid, and also containing the recommended dietary allowances of vitamins B6 and B12, in a randomized, double-blind, placebo-controlled, crossover trial in 75 men and women with coronary artery disease.
RESULTS: Plasma folic acid increased and plasma homocyst(e)ine decreased proportionately with the folic acid content of the breakfast cereal. Cereal providing 127 microg of folic acid daily, approximating the increased daily intake that may result from the FDA's enrichment policy, increased plasma folic acid by 31 percent (P=0.045) but decreased plasma homocyst(e)ine by only 3.7 percent (P= 0.24). However, cereals providing 499 and 665 microg of folic acid daily increased plasma folic acid by 64.8 percent (P<0.001) and 105.7 percent (P=0.001), respectively, and decreased plasma homocyst(e)ine by 11.0 percent (P<0.001) and 14.0 percent (P=0.001), respectively.
CONCLUSIONS: Cereal fortified with folic acid has the potential to increase plasma folic acid levels and reduce plasma homocyst(e)ine levels. Further clinical trials are required to determine whether folic acid fortification may prevent vascular disease. Until then, our results suggest that folic acid fortification at levels higher than that recommended by the FDA may be warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535664     DOI: 10.1056/NEJM199804093381501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Hyperhomocyst(e)inemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

Review 2.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Daily low-dose folic acid supplementation does not prevent nitroglycerin-induced nitric oxide synthase dysfunction and tolerance: a human in vivo study.

Authors:  Jonathan M DiFabio; Tommaso Gori; George Thomas; Sean Jedrzkiewicz; John D Parker
Journal:  Can J Cardiol       Date:  2010-11       Impact factor: 5.223

4.  Connective tissue: Vascular and hematological (blood) support.

Authors:  Nick Calvino
Journal:  J Chiropr Med       Date:  2003

5.  Homocysteine. Is it a modifiable risk factor for patients with coronary artery disease?

Authors:  C P Por; M F Evans
Journal:  Can Fam Physician       Date:  1998-11       Impact factor: 3.275

6.  Homocysteine and ischaemic stroke in men: the Caerphilly study.

Authors:  U B Fallon; P Elwood; Y Ben-Shlomo; J B Ubbink; R Greenwood; G D Smith
Journal:  J Epidemiol Community Health       Date:  2001-02       Impact factor: 3.710

7.  [Homocysteine as a cardiovascular marker and risk factor].

Authors:  K Pietrzik
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

8.  Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification.

Authors:  Tanya G K Bentley; Walter C Willett; Milton C Weinstein; Karen M Kuntz
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

9.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

10.  Increased plasma homocysteine levels in shift working bus drivers.

Authors:  P J F Martins; V D'Almeida; N Vergani; A B A Perez; S Tufik
Journal:  Occup Environ Med       Date:  2003-09       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.